Category: Finance
ASX Health Stocks: Healius rips higher as new CEO takes over; Nova Eye bags record US sales
Healius has new CEO Nove Eye reports record US sales in February Cynata says first patient has been enrolled in Phase 2 trial Healius [more…]
Specialist SME bank Avenue gains full APRA approval
Special Report: The digital bank is Australia’s newest and the only one that focuses on providing bank guarantees to small businesses and landlords. Avenue Bank [more…]
‘Boots on the ground’ as sampling reveals new 250m ‘Double Zone’ target at Mako Gold’s Napié project
Rock chip samples show up to 22.46g/t at Tchaga North’s Double Zone Double Zone now a high-priority drill target Mako Gold’s top brass travelling to [more…]
Strickland Metals bulks up as Bronco and Konik are combined into a single, large bulk tonnage gold target
Strickland Metals demonstrates Bronco and Konik are a single prospect that could be a large bulk tonnage target New interpretation explains previous interpretations between the [more…]
Top 10 at 11: Who has entered a farm-in deal and JV with Mineral Resources?
Stockhead’s Top 10 at 11, published each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, [more…]
Market Highlights: Records in sight for Gold, Bitcoin; US chipmaker joins S&P500 and 5 small caps to watch
Wall Street falls, Nvidia soars BTC nears all-time highs Gold to move even further? The ASX is poised to start flat on [more…]
OD6 Metals recovers up to 90% of magnet REEs across multiple prospects at Splinter Rock
Up to 90% of magnetic rare earths recovered in latest metallurgical work on Splinter Rock project Recoveries for all magnet rare earth oxides were achieved, [more…]
ASX-listed BluGlass possesses potentially one of the most critical, enabling technologies on the planet
Gallium nitride (GaN) lasers are an enabler for many future technologies ASX-listed BluGlass is one of only few companies in the world making this Stockhead [more…]
Rise and Shine: Everything you need to know before the ASX opens
Good morning. On Stockhead today, the 3c stock with a stronghold on one of the potentially most critical, enabling technologies on the planet, who [more…]
Dr Boreham’s Crucible: Does Clinuvel’s investor value run deeper than just ‘makes Scenesse’?
In a recent whimsical ‘news communique’ to investors, Clinuvel Pharmaceuticals (ASX:CUV) chief Dr Phillipe Wolgen dwells on the “the scale of human suffering and senseless [more…]
